Review: Update on Newer Antihypertensive Medicines and Interventions

Wu, Kathérine C.; Gerstenblith, Gary

doi:10.1177/1074248410368277

Cited by 5 publications

(4 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nebivolol has a unique hemodynamic profile, combining highly selective β 1 -adrergenic receptor antagonism with nitric oxide-mediated vasodilatory activity. Therefore, it is an effective antihypertensive agent . The nebivolol molecule contains four stereocenters and is marketed as a racemate of d -(+) and l -(−)-nebivolol 276 (Figure ).…”

Section: Drugs Affecting the Cardiovascular Systemmentioning

confidence: 99%

Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)

et al. 2013

View full text Add to dashboard Cite

Section: Drugs Affecting the Cardiovascular Systemmentioning

confidence: 99%

Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)

et al. 2013

View full text Add to dashboard Cite

“…Antihypertensive drugs play an important role in blood pressure regulation, however, for many patients targeted blood pressure is not achieved due to reasons such as insufficient medication, true drug resistance and non compliance. 127 Therefore there is a market for alternative solutions to the problem. Naturally occurring ACE inhibitory peptides derived from food proteins have been proven to be effective as in vivo antihypertensive agents.…”

Section: Discussionmentioning

confidence: 99%

The potential role of milk-derived peptides in cardiovascular disease

2011

View full text Add to dashboard Cite

Bioactive peptides derived from milk proteins are of particular interest to the food industry due to the potential functional and physiological roles that they demonstrate, particularly in relation to cardiovascular disease (CVD). By 2020 it is estimated that heart disease and stroke will become the leading cause of death and disability worldwide. Acute and chronic cardiovascular events may result from alterations in the activity of the renin-angiotensin aldosterone system and activation of the coagulation cascade and of platelets. Medications that inhibit angiotensin converting enzyme (ACE) are widely prescribed in the treatment and prevention of cardiovascular disease. ACE inhibitory peptides are of particular interest due to the presence of encrypted inhibitory peptide sequences. In particular, Ile-Pro-Pro and Val-Pro-Pro are fore runners in ACE inhibition, and have been incorporated into commercial products. Additionally, studies to identify additional novel peptides with similar bio-activity and the ability to withstand digestion during transit through the gastrointestinal tract are ongoing. The potential sources of such peptides in cheese and other dairy products are discussed. Challenges to the bio-availability of such peptides in the gastro intestinal tract are also reviewed. Activation of platelets and the coagulation cascade play a central role in the progression of cardiovascular disease. Platelets from such patients show spontaneous aggregation and an increased sensitivity to agonists which results in vascular damage and endothelial dysfunction associated with CVD. Peptide sequences exhibiting anti-thrombotic activity have been identified from fermented milk products. Studies on such peptides are reviewed and their effects on platelet function are discussed. Finally the ability of food derived peptides to decrease the formation of blood clots (thrombi) is reviewed. In conclusion, due to the widespread nature of cardiovascular disease, the identification of food derived compounds that exhibit a beneficial effect in such widespread areas of CVD regulation will have strong clinical potential. Due to the perception that food derived products have an acceptable risk profile they have the potential for widespread acceptance by the public. In this review, selected biological effects relating to CVD are discussed with a view to providing essential information to researchers.

show abstract

“…В связи с этим продолжаются поиск новых мишеней антигипертензивной терапии, разработка новых лекарственных средств, комбинаций лекарственных веществ с новыми свойствами, а также поиск новых молекул, которые отвечали бы основным требованиям к идеальному гипотензивному препарату (табл. 1) [7]. В связи с особой ролью в патогенезе АГ ренин-ангиотензин-альдостероновой системы (РААС), данная система всё также остаётся важнейшей мишенью для разработки новых гипотензивных средств (рис.…”

unclassified